TargeGen, Inc.
9380 Judicial Drive
San Diego
California
92121
United States
Tel: 858-678-0760
Fax: 858-678-0762
Website: http://www.targegen.com/
Email: info@targegen.com
About TargeGen, Inc.
TargeGen, Inc. is a privately held biopharmaceutical company based in San Diego. The company develops small molecule multi-target kinase inhibitors and combines a focus on vascular biology with expertise in small molecule medicinal chemistry. TargeGen compounds are primarily designed to inhibit vascular permeability, vascular proliferation, and inflammation. These biological processes are common to the pathology of many major human diseases. TargeGen's current compound in clinical development is TG101348 for the treatment of myeloproliferative diseases. The company has additional compounds in development for the treatment of inflammatory and ocular diseases.
TargeGen Drug Discovery
TargeGen's proprietary compounds are designed using advanced rational design techniques aided by computational chemistry and modeling technologies. TargeGen discovery programs are primarily focused on the development of src-kinase, PI3K and Jak-2 inhibitors.
TargeGen Investors Include:
- Forward Ventures
- VantagePoint Venture Partners
- Enterprise Partners
- William Blair Capital Partners/Chicago Growth Partners
- CDP Capital
- BB BIOTECH VENTURES
- Hambrecht & Quist Capital Management
- Innovis Investments
- A.M. Pappas & Associates
- CTI Life Sciences Fund
20 articles about TargeGen, Inc.
-
Sanofi-Aventis (France) Agrees to Acquire TargeGen, Inc. for $75 Million Upfront; May Spend as Much as $560 Million on Milestone Payments
6/30/2010
-
TargeGen, Inc. Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients
10/23/2009
-
TargeGen, Inc. Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
5/15/2009
-
TargeGen, Inc. Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 American Society of Hematology Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
12/2/2008
-
Partnership Between Industry And Academia Has Led To Human Clinical Trials Of A New Drug; Stem Cell Research Leads To Potential New Therapy For Rare Blood Disorder
4/10/2008
-
TargeGen, Inc. Announces Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
2/1/2008
-
TargeGen, Inc. Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients
12/7/2007
-
TargeGen, Inc. Initiates Multi-Center Phase II Clinical Trial Of TG100801, a Topically Applied Kinase Inhibitor In Macular Degeneration Patients
7/30/2007
-
TargeGen, Inc. Closes $40M Series 'D' Financing Round
7/12/2007
-
TargeGen, Inc. Receives 2007 James D. Watson Helix Award in the Private Company Category
5/9/2007
-
TargeGen, Inc. Appoints Martin Friedlander, M.D., Ph.D. to Scientific Advisory Board
4/13/2007
-
TargeGen, Inc. Announces Successful Completion of Phase I Clinical Trial of Topical AMD Drug TG100801
2/28/2007
-
TargeGen, Inc. Selects Jak2 Inhibitor Lead (TG101348) For Clinical Development As A Potential Therapy For Myeloproliferative Diseases Including Polycythemia Vera (PV)
1/8/2007
-
TargeGen, Inc. Initiates Phase I Clinical Trial Of Topical AMD Drug TG100801
11/1/2006
-
TargeGen, Inc. Receives USPTO Notice Of Allowance For U.S. Patent Application 10/679,209 Pertaining To TG100-115 And Related Compounds
10/17/2006
-
FDA Grants Fast Track Designation For TargeGen, Inc. TG100-115 Cardiovascular Compound
6/29/2006
-
TargeGen, Inc. CEO Peter Ulrich Receives 2006 Ernst & Young Entrepreneur Of The Year Award
6/15/2006
-
TargeGen, Inc. Presents Data For TG100801, A Topically Applied Compound For The Potential Treatment Of Major Eye Diseases Including Macular Degeneration
4/6/2006
-
TargeGen, Inc. Announces Planned Relocation Of Company Operations In January 2006 And Expansion Of Internal Capabilities
12/9/2005
-
BioPartnering Europe 2004 Exhibitor Profiles
10/11/2004